No connection

Search Results

ACH vs LFMD

ACH
Accendra Health, Inc.
BEARISH
Price
$2.11
Market Cap
$163.2M
Sector
Healthcare
AI Confidence
88%
LFMD
LifeMD, Inc.
BEARISH
Price
$3.47
Market Cap
$166.5M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
ACH
--
LFMD
--
Forward P/E
ACH
2.25
LFMD
7.8
P/B Ratio
ACH
-0.38
LFMD
7.0
P/S Ratio
ACH
0.02
LFMD
0.86
EV/EBITDA
ACH
4.68
LFMD
-20.27

Profitability

Gross Margin
ACH
20.78%
LFMD
85.72%
Operating Margin
ACH
8.08%
LFMD
-2.34%
Profit Margin
ACH
-12.45%
LFMD
7.4%
ROE
ACH
-196.39%
LFMD
-131.16%
ROA
ACH
3.75%
LFMD
-6.54%

Growth

Revenue Growth
ACH
1.5%
LFMD
-27.1%
Earnings Growth
ACH
--
LFMD
--

Financial Health

Debt/Equity
ACH
--
LFMD
0.27
Current Ratio
ACH
0.86
LFMD
1.25
Quick Ratio
ACH
0.1
LFMD
1.11

Dividends

Dividend Yield
ACH
--
LFMD
--
Payout Ratio
ACH
0.0%
LFMD
0.0%

AI Verdict

ACH BEARISH

The Advanced Deterministic Scorecard reveals a critically weak financial health profile with a Piotroski F-Score of just 1/9, indicating severe operational and financial distress. Despite a low forward P/E of 2.25 and a Price/Sales ratio of 0.02 suggesting apparent cheapness, negative profitability metrics—including a -12.45% profit margin and -196.39% ROE—undermine valuation appeal. The company faces acute liquidity risk with a current ratio of 0.86 and a near-zero quick ratio of 0.10, while earnings have collapsed with a YoY decline of 40.5%. Although insider sentiment is neutral and analysts project a 92% upside to a $4.08 target, the deteriorating fundamentals and lack of cash flow transparency present substantial risk.

Strengths
Low forward P/E of 2.25 may attract contrarian or value-seeking investors
Operating margin of 8.08% indicates some pricing power or cost control at operational level
Gross margin of 20.78% is relatively healthy for medical distribution sector
Risks
Piotroski F-Score of 1/9 signals extreme financial weakness and high risk of continued underperformance
Negative Price/Book of -0.38 and unreported Altman Z-Score indicate likely insolvency risk or balance sheet instability
Current and quick ratios (0.86 and 0.10) suggest imminent liquidity crisis and inability to meet short-term obligations
LFMD BEARISH

LFMD exhibits severe financial deterioration, highlighted by a weak Piotroski F-Score of 2/9 and a catastrophic Q/Q revenue decline of 88.98%. While the company maintains a low debt-to-equity ratio, the combination of negative operating margins, a deeply negative ROE (-131.16%), and a 0/4 earnings beat record over the last four quarters indicates a business in crisis. Despite a high analyst target price of $9.88, the fundamental data and technical trend (0/100) suggest a value trap scenario.

Strengths
High gross margins (85.72%)
Low debt-to-equity ratio (0.27)
Reasonable current ratio (1.25)
Risks
Severe revenue collapse (-88.98% Q/Q)
Consistent earnings misses (0/4 beats in last 4 quarters)
Deeply negative Return on Equity (-131.16%)

Compare Another Pair

ACH vs LFMD: Head-to-Head Comparison

This page compares Accendra Health, Inc. (ACH) and LifeMD, Inc. (LFMD) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile